Ингибирование МАР-киназного пути в лечении метастатической меланомы кожи
Аннотация
Приведены результаты ряда современных клинических исследований у больных BRAF мутированной диссеминированной меланомой с использованием ингибиторов BRAF и МЕК. Показана возможность улучшения результатов лечения с помощью их комбинаций. Стратегия комбинированной таргетной терапии обсуждена с позиций преодоления приобретенной резистентности к ингибиторам BRAF. Проанализированы причины кожной токсичности при лечении BRAF и МЕК ингибиторами, показаны возможности снижения этого нежелательного явления при комбинированном применении ингибиторов BRAF и МЕК.
Об авторе
Любовь Юрьевна Владимирова
ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава России
Россия
г. Ростов-на-Дону
Россия
г. Ростов-на-Дону
Список литературы
1. Владимирова Л. Ю. Применение ингибиторов МЕК в онкологии: результаты и перспективы // Успехи современного естествознания. – 2015. – № 3.– С. 18–30.
2. Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol 2010; 49(9):978–86.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27(36):6199–206.
4. La Porta CA. Drug resistance in melanoma: new perspectives. Curr Med Chem 2007; 14(4):387–91.
5. Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 2009; 27(6):614–25.
6. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26):2507–16.
7. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26):2517–26.
8. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of longterm survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [Abstract 24]. Presented at: European Cancer Congress. Amsterdam, The Netherlands, September 27–October 1, 2013.
9. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26):2455–65.
10. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26):2443–54.
11. Greaves WO, Verma S, Patel KP, et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 2013; 15(2):220–6.
12. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29(10):1239–46.
13. Platz A, Egyhazi S, Ringborg U, et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1(4):395–405.
14. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24(26):4340–6.
15. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9):809–19.
16. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467(7315):596–9.
17. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366(8): 707–14.
18. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26(4):527–34.
19. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutationpositive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15(3): 323–32.
20. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379(9829):1893–901.
21. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31(26):3205–11.
22. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380(9839):358–65.
23. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13(11):1087–95.
24. Dummer R, Goldinger SM, Turtschi CP, et al. Vemurafenib in patients with BRAF mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50(3):611–21.
25. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366(3): 207–15.
26. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367(18):1694–703.
27. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30(19):2375–83.
28. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31(14):1767–74.
29. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468(7326):973–7.
30. Straussman R, Morikawa T, Shee K, et al. Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012; 487(7408):500–4.
31. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18(6):683–95.
32. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factordriven resistance to anticancer kinase inhibitors. Nature 2012; 487(7408):505–9.
33. Yadav V, Zhang X, Liu J, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/ Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 2012; 287(33): 28087–98.
34. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439(7074):358–62.
35. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22(22):4456–62.
36. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16(6):1924–37.
37. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, openlabel, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012; 18(2):555–67.
38. Larkin J. Yan Y., McArthur G. et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma // J Clin Oncol 33, 2015 (suppl; abstr 9006).
39. Long G., Stroyakovskiy D., Gogas H. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial // Lancet, 2015 Vol.386, No. 9992, p.444–451.
Рецензия
Для цитирования:
Владимирова Л.Ю. Ингибирование МАР-киназного пути в лечении метастатической меланомы кожи. Злокачественные опухоли. 2015;(4s2):12-15.
Просмотров: 662
Послать статью по эл. почте 